167 related articles for article (PubMed ID: 31332810)
1. Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study.
Lee I; Adimadhyam S; Nutescu EA; Zhou J; Asfaw AA; Sweiss KI; Patel PR; Calip GS
Pharmacotherapy; 2019 Sep; 39(9):921-928. PubMed ID: 31332810
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Patel JN; Jiang C; Hertz DL; Mulkey FA; Owzar K; Halabi S; Ratain MJ; Friedman PN; Small EJ; Carducci MA; Mahoney JF; Kelley MJ; Morris MJ; Kelly WK; McLeod HL
Cancer; 2015 Apr; 121(7):1025-31. PubMed ID: 25417775
[TBL] [Abstract][Full Text] [Related]
3. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
4. Impact of venous thromboembolism on incidence of arterial thromboembolism - An analysis of German outpatient claims data.
Keller K; Kohring C; Farmakis IT; Valerio L; Barco S; Bätzing J; Akmatov MK; Konstantinides S; Münzel T; Hobohm L; Holstiege J
Thromb Res; 2023 Jun; 226():9-17. PubMed ID: 37079980
[TBL] [Abstract][Full Text] [Related]
5. Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider.
Hofmann S; Schmidt MA; Weissmann T; Eyüpoglu I; Strnad A; Semrau S; Fietkau R; Putz F; Lettmaier S
J Neurooncol; 2020 Jun; 148(2):373-379. PubMed ID: 32409944
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of venous and arterial thromboembolism in patients with colorectal cancer receiving cetuximab-based combination chemotherapy: A population-based study in Korea.
Yhim HY; Lee J; Kim KH; Kim SA; Lee JY; Hwang HG; Hong J; Lee JO; Bang SM
Thromb Res; 2023 Nov; 231():50-57. PubMed ID: 37804738
[TBL] [Abstract][Full Text] [Related]
7. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.
Chen SY; Wu N; Gulseth M; LaMori J; Bookhart BK; Boulanger L; Fields L; Schein J
J Manag Care Pharm; 2013 May; 19(4):291-301. PubMed ID: 23627575
[TBL] [Abstract][Full Text] [Related]
8. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
[TBL] [Abstract][Full Text] [Related]
9. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.
Detti B; Scoccianti S; Teriaca MA; Maragna V; Lorenzetti V; Lucidi S; Bellini C; Greto D; Desideri I; Livi L
Radiol Med; 2021 Sep; 126(9):1249-1254. PubMed ID: 34081269
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A
Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Recurrent Venous Thromboembolism or Arterial Thrombotic Events during and after Anticoagulation for a First Venous Thromboembolism.
Noumegni SR; Tromeur C; Hoffmann C; Mao RL; Moigne EL; Moreuil C; Mansourati V; Nasr B; Gentric JC; Guegan M; Poulhazan E; Bressollette L; Lacut K; Didier R; Couturaud F
Semin Thromb Hemost; 2023 Oct; 49(7):688-701. PubMed ID: 36252603
[TBL] [Abstract][Full Text] [Related]
13. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
Cha Y; Kim YJ; Lee SH; Kim TM; Choi SH; Kim DW; Park CK; Kim IH; Kim JH; Kim E; Choi B; Kim CY; Kim IA; Heo DS
Cancer Res Treat; 2017 Jan; 49(1):129-140. PubMed ID: 27188199
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
[TBL] [Abstract][Full Text] [Related]
15. Risk of thromboembolism according to statin treatment in patients with cancer: A nationwide nested case-control study.
Yoo J; Jeon J; Baik M; Kim J
Thromb Res; 2024 Mar; 235():32-40. PubMed ID: 38295599
[TBL] [Abstract][Full Text] [Related]
16. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
17. High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
Kang A; Antonelou M; Wong NL; Tanna A; Arulkumaran N; Tam FWK; Pusey CD
J Rheumatol; 2019 Mar; 46(3):285-293. PubMed ID: 30385704
[TBL] [Abstract][Full Text] [Related]
18. A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
Villani V; Fabi A; Tanzilli A; Pasqualetti F; Lombardi G; Vidiri A; Gonnelli A; Molinari A; Cantarella M; Bellu L; Terrenato I; Carosi M; Maschio M; Telera SM; Carapella CM; Cognetti F; Paiar F; Zagonel V; Pace A
Future Oncol; 2019 May; 15(15):1717-1727. PubMed ID: 30977687
[No Abstract] [Full Text] [Related]
19. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study.
Johannesdottir SA; Horváth-Puhó E; Dekkers OM; Cannegieter SC; Jørgensen JO; Ehrenstein V; Vandenbroucke JP; Pedersen L; Sørensen HT
JAMA Intern Med; 2013 May; 173(9):743-52. PubMed ID: 23546607
[TBL] [Abstract][Full Text] [Related]
20. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]